Laura Deming

Deming has articulated a concrete and ambitious future vision around reversible cryopreservation as a staged path from organ preservation to whole-body cryo or hibernation-like medicine. The evidence is unusually specific for a future_vision dimension because it includes a roadmap, near-term commercial/medical use case, and longer-term endpoint. However, the record provided is narrow, mostly self-published, and lacks broader destination statements explicitly about ending aging or extending healthy lifespan beyond the cryopreservation pathway.

Primary citation evidence shows essentially no direct scientific publication impact: h-index 0, i10-index 0, 0 citations, and only one indexed work. The remaining evidence points mainly to investing, public interests, and self-published claims about cryopreservation work, but does not independently establish field-shaping scientific results.

The dimension applies because Deming is described as a longevity-focused venture capitalist who founded and ran The Longevity Fund, an early dedicated longevity VC vehicle. That is directly relevant institution-building and capital allocation, and her tagline suggests catalytic category-building. However, the provided evidence contains no disclosed investment count, fund size, portfolio names, personal capital at risk, or independently corroborated deployment amounts. The only concrete recent funding figure concerns Until Labs raising capital from others, not Deming deploying capital. Under the independence gate, the strong capital-deployment claim is supported mainly by an unknown-source dossier and self-published/promotional material, so the score should not exceed 5.

Deming shows strong strategic taste evidence: a coherent, early, high-risk thesis around making longevity biotech fundable, first through The Longevity Fund and later through Until Labs. The Until strategy is especially thesis-coherent because it stages a speculative whole-body cryopreservation ambition through a nearer-term organ-preservation business case. Confidence is limited because most evidence is self-published and the record lacks disclosed investment portfolio details, outcomes, or independent validation of counterfactual importance.

Field creation applies directly: the evidence identifies Deming as founder of The Longevity Fund, described as an early longevity-focused VC vehicle, plus later founder roles at Loyal and Until Labs. That supports meaningful creation of funding and company-building paths for longevity work. However, the strongest category-creation claim is mainly from structured facts and an unknown-independence dossier, while independent or primary corroboration of broad field-level impact is limited in the provided evidence, so the score should not be field-defining.

Bravery/conviction applies. The evidence shows Laura Deming publicly attaching her name and credibility to reversible cryopreservation and an explicit roadmap toward whole-body cryo, a position outside mainstream medical consensus. This supports contrarian public stance and some public-risk conviction, but the evidence is mostly self-published, recent, and does not document major personal downside, sustained criticism, or direct self-experimentation risk.

The dimension applies: Deming's work is explicitly about creating and financing longevity companies, and the evidence supports some multiplier effect through founding multiple organizations and public recruiting/capital-formation activity. However, the strongest claims about field-level leverage, major capital attraction, and making longevity biotech fundable are supported mainly by self-published, promotional, or unknown-independence evidence, so the independence gate caps the score at 5.